Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy.

20 Post-hoc analysis of the subpopulation with hereditary ATTR-CM accompanying neuropathy in the APOLLO study showed a highly significant reduction in NT-proBNP concentration among patients receiving patisiran compared with those on placebo. 22 Of note, the trial design of ATTRibute-CM, a current global phase III clinical trial evaluating the novel transthyretin (TTR) stabiliser acoramidis in ATTR-CM, includes a part A for which the primary endpoint is a comparison of ∆ 6MWT distance from enrolment to 12 months between the treatment and placebo groups. 25 Although ∆ 6MWT distance undoubtedly provides a valuable functional assessment, it is noteworthy that it did not predict survival in our cohort.

also in 132,142 other papers